“Synthesis and antifungal activity of new N-[1-aryl-2-(1H-imidazol-1-yl and 1H-1,2,4-triazol-1-yl)-1-ethylidene]-N’-2,4-dichloro-phenylhydrazine derivatives”.

Systemic fungal infections have emerged as important causes of morbidity and mortality in immunocompromised patients (e.g., AIDS, cancer chemotherapy, organ or bone marrow transplantation). In addition, hospital-related infections in patients not previously considered at risk (e.g. patients on an intensive care unit) have become a cause of major health concern. An the other hand the increased incidence of severe opportunistic fungal infection together with the rise up of resistance to many antifungal drugs bring to need to development of new antifungal compounds. The azole compounds interact at the target enzyme cytocrome P450-dependent lanosterol 14α-demethylase in the ergosterol-biosynthesis pathway. Our search of new antifungal compounds was performed through a preliminary computer modeling of drug/enzyme complexes beginning from N1-[1-aryl-2-(1H-imidazol-1-yl and 1H-1,2,4-triazol-1-yl)ethylidene]-pyridine-2-carboxamidrazone derivates (1)[1]. Some of these compounds have exhibited a remarkable antifungal activity.